Mission Statement, Vision, & Core Values (2026) of CG Oncology, Inc. Common stock.

CG Oncology, Inc. is on a mission to deliver bladder-sparing immunotherapies that preserve function and dignity for urologic cancer patients, advancing its lead investigational oncolytic immunotherapy, cretostimogene grenadenorepvec, through pivotal studies such as the phase three trials BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC, with a company vision centered on enabling patients to live with enhanced quality of life and a values-driven culture-patient-centered, integrity, perseverance, collaboration, well-being, and innovation-that supports clinical progress and commercialization efforts (as reflected in CG Oncology's common stock, CGON, trading at $40.08 USD as of December 23, 2025).

CG Oncology, Inc. Common stock (CGON) - Intro

• Estimated new bladder cancer cases in the U.S.: ~82,000 annually (most recent national estimates).
• NMIBC comprises roughly 70-75% of newly diagnosed bladder cancers.
• Recurrence rates for NMIBC are high - typically 50-70% over time - driving the need for durable, bladder‑sparing options.
• Radical cystectomy carries substantial morbidity; therapies that reduce cystectomy rates have significant quality‑of‑life impact.

• Mission: Create a world where urologic cancer patients benefit from innovative immunotherapies, enabling them to live with dignity and enhanced quality of life.
• Vision: Become the global leader in bladder‑sparing immunotherapeutics by delivering approved, broadly accessible treatments for NMIBC and related urologic malignancies.
• Strategic priorities: Advance pivotal trials (BOND‑003, PIVOT‑006), secure regulatory approvals, expand manufacturing and commercialization readiness, and pursue additional indications where oncolytic approaches can provide durable benefit.

• Patient‑centered care: Clinical development decisions driven by patient outcomes and quality of life metrics.
• Integrity: Transparent data sharing and ethical conduct across research and business operations.
• Perseverance: Commitment to overcoming technical and regulatory challenges inherent in late‑stage oncology development.
• Collaboration: Partnering with academic centers, CROs, and regulatory agencies to accelerate trials and broaden investigator engagement.
• Well‑being: Supporting employee mental and physical health to sustain long‑term innovation.
• Innovation: Continuous improvement of oncolytic platforms and combination strategies to increase response durability.

• As of December 23, 2025, CG Oncology, Inc. Common stock (CGON) is trading at $40.08 USD, reflecting investor interest in the company's late‑stage pipeline and upcoming clinical readouts.
• Late‑stage readouts and regulatory interactions are primary near‑term value drivers for shareholders; successful pivotal results can materially impact market valuation.

• Enrollment progress and top‑line efficacy/safety results from BOND‑003 (high‑risk BCG‑unresponsive NMIBC).
• PIVOT‑006 enrollment and interim analyses for intermediate‑risk NMIBC.
• Regulatory meetings (e.g., FDA interactions) regarding registrational pathways and potential accelerated approval options.
• Manufacturing scale‑up and commercialization planning ahead of potential approval.

CG Oncology, Inc. Common stock (CGON) - Overview

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's mission and strategic priorities center on developing innovative immunotherapies that preserve bladder function, enhance quality of life, and respect patient dignity.

Mission Statement

• To create a world where urologic cancer patients can benefit from innovative immunotherapies, enabling them to live with dignity and experience improved quality of life.
• To advance treatments that preserve bladder function and reduce the need for invasive procedures such as radical cystectomy.
• To pursue cutting-edge science in immuno-oncology with a patient-centric focus on individualized, compassionate care.

Vision

• Establish a new standard of care in bladder cancer that shifts treatment paradigms from organ removal to organ preservation.
• Deliver commercially viable immunotherapy options that are accessible to eligible patients worldwide.
• Become a trusted partner to clinicians and patients by generating robust clinical evidence that demonstrates meaningful survival, bladder preservation, and quality-of-life benefits.

Core Values

• Patient-Centricity: Prioritizing dignity, autonomy, and quality of life in all development decisions.
• Scientific Rigor: Commitment to robust, reproducible clinical science and evidence-based development.
• Innovation: Pursuing novel immunotherapeutic approaches and translational science to address unmet needs.
• Integrity & Transparency: Clear communication with patients, caregivers, clinicians, and investors.
• Collaboration: Building partnerships across academia, clinical networks, and industry to accelerate impact.

Chapter-Relevant Data & Market Context

To contextualize CG Oncology's mission and programs, key epidemiology and market metrics for bladder cancer and bladder-preservation therapeutics are summarized below.

How Mission Drives Development Strategy

• Clinical design prioritizes bladder preservation endpoints (e.g., avoidance of cystectomy, recurrence-free survival, organ function metrics).
• Patient-reported outcomes and quality-of-life measures are embedded into trials to quantify dignity and daily-life impact.
• Commercial planning emphasizes payer engagement and health‑economic evidence to support reimbursement for bladder-sparing approaches.

For a detailed financial overview and investor-focused analysis, see: Breaking Down CG Oncology, Inc. Common stock Financial Health: Key Insights for Investors

CG Oncology, Inc. Common stock (CGON) - Mission Statement

• Primary focus: development and commercialization of intravesical oncolytic immunotherapies for non‑muscle invasive bladder cancer (NMIBC), with an emphasis on BCG‑unresponsive disease.
• Patient-centered outcomes: preserving bladder function, reducing need for radical cystectomy, and improving quality of life metrics (urinary function, pain reduction, emotional well‑being).
• Clinical emphasis: accelerated pathways and registrational trials targeted at high‑unmet‑need populations to shorten time to patient access.

• Directing R&D toward endpoints that matter to patients and payers (durable complete response, cystectomy‑free survival, patient‑reported outcomes).
• Using biomarker‑driven development and combination immunotherapy strategies to increase response rates while minimizing systemic toxicity.
• Collaborating with urology and oncology centers to ensure real‑world data collection and rapid adoption if therapies demonstrate clinical benefit.

• Dignity: prioritize treatments that allow patients to retain normal organ function and daily living capabilities.
• Innovation: pursue novel immunotherapeutic modalities and combination approaches to improve response durability.
• Transparency: commit to rigorous clinical data reporting, real‑world evidence generation, and open engagement with regulators and payers.
• Collaboration: partner with academic centers, urology specialists, and patient advocacy groups to align development with patient needs.

CG Oncology, Inc. Common stock (CGON) - Vision Statement

• Patient-Centered: Prioritizing treatments that reduce morbidity, avoid radical cystectomy where possible, and emphasize functional outcomes and quality of life.
• Integrity: Upholding ethical practices, regulatory compliance, and transparent communication with investors, patients, and healthcare partners.
• Perseverance: Sustaining long-term R&D commitment through iterative clinical development and adaptive problem-solving in the face of clinical and regulatory challenges.
• Collaboration: Partnering with academic centers, CROs, patient advocacy groups, and strategic investors to accelerate development and broaden access.
• Well-Being: Supporting employee health, safety, and work-life balance through competitive benefits and wellness programs.
• Innovation: Investing in cutting-edge modalities and translational research to deliver differentiated therapeutic options in bladder cancer.

• Clinical Excellence: Advance lead candidates through rigorously designed trials with patient-centered endpoints (oncologic control, organ preservation, functional outcomes).
• Data Transparency: Report clinical and financial milestones with clarity to support ethical investor engagement and patient trust.
• Capital Stewardship: Manage cash runway and capital allocation to maximize probability of clinical success while minimizing dilution.
• Commercial Readiness: Build pathways for reimbursement and adoption emphasizing cost-effectiveness and value to payers and providers.

• Comprehensive benefits package including medical, dental, vision, mental health resources, and flexible time-off policies.
• Professional development stipends, continuing-education allowances, and cross-functional career pathways to retain scientific talent.
• Safety protocols and wellness programs designed to support remote and on-site employees engaged in R&D and clinical operations.

• Pipeline Milestones: Emphasis on achieving clinical readouts that demonstrate both oncologic efficacy and organ preservation endpoints.
• Cash Management: Prioritize runway-extension strategies tied to milestone-based financing and strategic collaborations.
• Regulatory Pathway: Pursue accelerated or adaptive regulatory designations when supported by compelling efficacy and safety data.

• Academic medical centers for investigator-initiated trials and translational biomarker programs.
• Contract research organizations (CROs) for scalable trial execution and data management.
• Patient advocacy and payer dialogues to align trial endpoints with real-world value and adoption requirements.